|
COVER STORY
|
 VC funding—making a difference
Biotech being an inherently risky business, many private funding agencies appear reluctant to supply cash. Here is a look at the current biotech financing scenario and the withering gaps in funding.
|
|
|
BIOSPECIAL
|
Biotech firms head towards new direction
Realizing the fact that traditional approach will not yield optimal results in the market, Indian drug makers are heading towards a new direction to strengthen their business. With this series on business models, BioSpectrum will highlight those Indian biotech companies that have embarked on novel strategies to augment their growth. |
Biofuel sector gears up for growth
Understanding the need for an alternative fuel, the Government of India and the state governments have promoted the production and consumption of biodiesel since the year 2000. |
"Demand for biodiesel will see a steady rise"
CS Jadhav, director – marketing, Nandan Biomatrix, Hyderabad. |
"Business prospects of biofuel are promising"
KV Subramaniam, president and CEO, Reliance Life Sciences, Mumbai |
"Oncology market growing at 20% in APAC region"
Like China, India too offers huge opportunities for companies to offer anti-cancer drugs because of increase in mortality rate due to cancer. In 2007, the oncology market size registered close to 70 percent growth with a market size of $54 million (Rs 259 crore). |
|
| BIOANALYSIS |
|
|
|
BIOBUSINESS |
Kemwell eyes biologics frontiers
Kemwell, the leading provider of contract manufacturing and development services for the top 10 pharmaceutical companies in the world and manufacturers of five of the top 10 pharmaceutical brands in India, is now making its foray into biologics. |
 |
|
|
EVENT |
|
|
|
|
| BIOCOLUMN |
India’s Swine Flu Bravado
- Narayanan Suresh, group editor, BioSpectrum
An unprepared health system is endangering the nation’s future and the tardy manner in which the country’s health authorities responded to advance warning from global experts about the impending pandemic is nothing but callousness towards the citizens.
|
Commercialization of ES/iPS cell drug screening technology
- Chikafumi Yokoyama, CEO, ReproCELL, Japan
|
 |
| BIOSUPPLIERS |
"Multiple buyers are needed for maximum sensitivity, specificity"
- Dr Jehangir Mistry, director, R&D, Bioscience Division, Millipore Corporation, US
|
|
| BIOTALK |
"Kerry will expand its presence in Asia Pacific markets"
- Rizwan A Khan, senior sales director, LATAM & APAC, Sheffield Pharma, Kerry BioSciences, US
|
|
|
